Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Cornea ; 41(2): 254-256, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1636854

ABSTRACT

ABSTRACT: As the understanding of COVID-19 infection becomes better, it is being recognized as a complex multisystem pathology rather than just affecting the lungs. Several ocular findings have been documented by researchers in individuals infected with COVID-19, and ocular symptoms may even be the first presenting feature of COVID-19 infection in 2.26% individuals. Several countries have started vaccination with inactivated or live vaccines to combat this pandemic, and varied side effects have been reported after vaccination. Few cases of herpes zoster have previously been reported in elderly patients with comorbidities after receiving COVID-19 vaccines. In this article, the authors described 2 interesting cases of herpes zoster ophthalmicus (HZO) after receiving a live COVID-19 vaccine. The first case was a 35-year-old immunocompetent man who developed HZO 3 days postvaccine. The second case was a 40-year-old immunocompetent man who developed HZO 28 days postvaccine. To the best of our knowledge, no literature to date has described HZO after live vaccine.


Subject(s)
COVID-19/prevention & control , Conjunctivitis, Viral/etiology , Herpes Zoster Ophthalmicus/etiology , Vaccination/adverse effects , Acyclovir/therapeutic use , Administration, Ophthalmic , Administration, Oral , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Drug Therapy, Combination , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , SARS-CoV-2/immunology , Valacyclovir/therapeutic use , Visual Acuity/physiology
2.
Cornea ; 41(2): 254-256, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1483572

ABSTRACT

ABSTRACT: As the understanding of COVID-19 infection becomes better, it is being recognized as a complex multisystem pathology rather than just affecting the lungs. Several ocular findings have been documented by researchers in individuals infected with COVID-19, and ocular symptoms may even be the first presenting feature of COVID-19 infection in 2.26% individuals. Several countries have started vaccination with inactivated or live vaccines to combat this pandemic, and varied side effects have been reported after vaccination. Few cases of herpes zoster have previously been reported in elderly patients with comorbidities after receiving COVID-19 vaccines. In this article, the authors described 2 interesting cases of herpes zoster ophthalmicus (HZO) after receiving a live COVID-19 vaccine. The first case was a 35-year-old immunocompetent man who developed HZO 3 days postvaccine. The second case was a 40-year-old immunocompetent man who developed HZO 28 days postvaccine. To the best of our knowledge, no literature to date has described HZO after live vaccine.


Subject(s)
COVID-19/prevention & control , Conjunctivitis, Viral/etiology , Herpes Zoster Ophthalmicus/etiology , Vaccination/adverse effects , Acyclovir/therapeutic use , Administration, Ophthalmic , Administration, Oral , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Conjunctivitis, Viral/diagnosis , Conjunctivitis, Viral/drug therapy , Drug Therapy, Combination , Herpes Zoster Ophthalmicus/diagnosis , Herpes Zoster Ophthalmicus/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , SARS-CoV-2/immunology , Valacyclovir/therapeutic use , Visual Acuity/physiology
3.
Future Microbiol ; 16(11): 769-776, 2021 07.
Article in English | MEDLINE | ID: covidwho-1308246

ABSTRACT

The current study presents two patients who lived in a rural family with close contact and suffered from rapidly progressive pneumonia. Chest computed tomography images and lymphocytopenia indicated the possibility of COVID-19 infection, but antibody and nucleic acid tests excluded this possibility. Negative results were obtained from corresponding tests for pneumococcal, adenovirus, fungal and legionella infection. Metagenomics analysis and subsequent antibody tests confirmed mycoplasma pneumonia. After treating with moxifloxacin, both patients recovered well and left the hospital. In terms of complicated infectious disease, consideration of atypical pathogens and medical and epidemiological history were important for differential diagnosis of COVID-19; metagenomics analysis was useful to provide direct references for diagnosis.


Subject(s)
Moxifloxacin/therapeutic use , Pneumonia, Mycoplasma/diagnosis , Adolescent , Adult , COVID-19 , DNA, Bacterial , Diagnosis, Differential , Feces/microbiology , Female , Humans , Male , Metagenomics , Mycoplasma pneumoniae/genetics , Mycoplasma pneumoniae/isolation & purification , Pneumonia, Mycoplasma/drug therapy , Sputum/microbiology , Young Adult
5.
Eur J Ophthalmol ; 31(2): NP161-NP166, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-671272

ABSTRACT

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus causing an ongoing pandemic in 2020. Although the symptomatic patients infected by SARS-CoV-2 generally show respiratory distress, atypical manifestations such as conjunctivitis are also observed. A series of cases are reported in which reverse transcriptase polymerase chain reaction (RT-PCR) testing on tears had demonstrated the presence of the virus. However, the transmission of the virus through ocular fluids remains unknown. CASE DESCRIPTION: In this case report, the development of conjunctivitis is presented as the sole symptom of a new coronavirus disease 2019 (COVID-19) in an emergency health care worker. The patient's first application was to the ophthalmology clinic due to redness, stinging, tearing, and photophobia for one day in the right eye. The patient had no symptoms of fever, cough, shortness of breath, or fatigue. Two days later, the RT-PCR test, blood analysis, and chest computed tomography (CT) were applied to the patient for being in contact with a COVID positive patient. Conjunctival swabs did not identify SARS-CoV-2 by RT-PCR. However, nasopharyngeal swab and blood test confirmed the diagnosis of COVID-19. Chest CT did not show pneumonia. CONCLUSION: This phenomenon shows that conjunctivitis may occur as a sole manifestation of COVID-19 which needs to be carefully evaluated by health care workers and eye care professionals during the pandemic.


Subject(s)
COVID-19/diagnosis , Conjunctivitis, Viral/diagnosis , Eye Infections, Viral/diagnosis , SARS-CoV-2/isolation & purification , Administration, Ophthalmic , Adult , Anti-Bacterial Agents/therapeutic use , COVID-19/drug therapy , COVID-19 Nucleic Acid Testing , Conjunctivitis, Viral/drug therapy , Eye Infections, Viral/drug therapy , Humans , Male , Moxifloxacin/therapeutic use , Nurses , Occupational Exposure , Ophthalmic Solutions , Pneumonia, Viral/diagnostic imaging , RNA, Viral/analysis , SARS-CoV-2/genetics , Tears/virology , Tomography, X-Ray Computed
6.
Expert Rev Mol Diagn ; 21(2): 245-250, 2021 02.
Article in English | MEDLINE | ID: covidwho-1048072

ABSTRACT

Introduction: This study aimed to assess the correlation between nucleic acid amplification test (real-time reverse transcription-polymerase chain reaction, RT-PCR) positivity of patients presenting with suspected COVID-19 and pneumonic infiltration consistent with COVID-19-specific pneumonia diagnosis on thoracic computed tomography (CT), with symptoms, laboratory findings, and clinical progression.Methods: The study included 286 patients (female:male 131:155; mean age, 53.3 ± 17.9 years) who were divided into two groups according to their RT-PCR test results. The symptoms, laboratory examinations, clinical findings, and thoracic CT imaging of the patients were evaluated.Results: While the physical examination, comorbidities, and total CT scores were similar between the groups, taste/smell abnormalities were observed more frequently in the PCR-positive group. The use of moxifloxacin, lopinavir/ritonavir, and tocilizumab was higher in the PCR-positive group (p = 0.016, p < 0.001, and p = 0.002, respectively). The duration of hospitalization, intensive care requirement, and mortality rate of the studied groups did not differ between the groups.Conclusions: Among patients presenting with suspected COVID-19 and pneumonic infiltration consistent with COVID-19 on thoracic CT, the symptoms, physical examination, total CT scores, duration of hospitalization, intensive care requirement, and mortality rate were similar between RT-PCR-positive and RT-PCR-negative patients. However, PCR-positive patients appeared to require more specific treatments.


Subject(s)
COVID-19 Nucleic Acid Testing , COVID-19/diagnostic imaging , COVID-19/mortality , Real-Time Polymerase Chain Reaction , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19/drug therapy , Comorbidity , Female , Humans , Lopinavir/therapeutic use , Male , Middle Aged , Moxifloxacin/therapeutic use , Olfaction Disorders/complications , Radiography, Thoracic , Ritonavir/therapeutic use , Taste Disorders/complications , Tomography, X-Ray Computed , Turkey/epidemiology
7.
Medicine (Baltimore) ; 100(2): e23923, 2021 Jan 15.
Article in English | MEDLINE | ID: covidwho-1039765

ABSTRACT

ABSTRACT: Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2; no specific effective medication to treat the disease has been identified to date. We aimed to investigate the administered medications and intervention times for patients who completely recovered from COVID-19.This single-center, retrospective, observational study included 55 patients with COVID-19 who were transferred to Shenyang Sixth People's Hospital between January 20 and March 15, 2020. Data on demographics, symptoms, laboratory indicators, treatment processes, and clinical outcomes were collected. Administered drugs and intervention times were compared in 47 and 8 patients with mild and severe symptoms, respectively.All 55 patients recovered. Fifty-three patients (96.36%) received antiviral therapy, including 45 in the mild group (median treatment: 14 days; 17 received umifenovir) and all 8 severe-group patients (median treatment: 17.5 days; 4 received lopinavir/ritonavir). Twenty-nine patients (52.72%) were administered antibiotics, including 21 in the mild group (median treatment: 13.5 days; 15 received moxifloxacin) and all 8 in the severe group (median treatment: 9 days; 2 received linezolid). Moreover, 7 patients (12.72%) were treated with glucocorticoids and 9 (16.36%) with immunomodulators.Given the 100% recovery rate, early administration of antiviral drugs can be considered. Umifenovir may benefit patients with mild symptoms, while lopinavir/ritonavir may benefit those with severe symptoms. Prophylactic administration of common antibiotics may reduce the risk of co-infection. The use of glucocorticoids is usually not necessary. Randomized, double-blind, and controlled trials remain necessary for more accurate conclusions.


Subject(s)
COVID-19/drug therapy , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , China , Female , Glucocorticoids/therapeutic use , Humans , Immunologic Factors/therapeutic use , Indoles/therapeutic use , Linezolid/therapeutic use , Lopinavir/therapeutic use , Male , Middle Aged , Moxifloxacin/therapeutic use , Retrospective Studies , Ritonavir/therapeutic use
8.
Arch Med Res ; 51(7): 741-742, 2020 10.
Article in English | MEDLINE | ID: covidwho-1023463

ABSTRACT

Since the beginning of the COVID-19 pandemic, researchers have focused on repurposing of existing antibiotics, antivirals and anti-inflammatory drugs to find an effective therapy. Fluoroquinolones are broad spectrum synthetic antimicrobial agents, being chemical derivatives of quinoline, the prodrome of chloroquine. Interestingly, fluoroquinolones may exert antiviral actions against vaccinia virus, papovavirus, CMV, VZV, HSV-1, HSV-2, HCV and HIV. A recent in silico study has shown that the fluoroquinolones, ciprofloxacin and moxifloxacin, may inhibit SARS-CoV-2 replication by exhibiting stronger capacity for binding to its main protease than chloroquine and nelfinavir, a protease inhibitor antiretroviral drug. Remarkably, fluoroquinolones have shown multiple immunomodulatory actions leading to an attenuation of the inflammatory response through the inhibition of pro-inflammatory cytokines. Noteworthy, respiratory fluoroquinolones, levofloxacin and moxifloxacin, constitute fist line therapeutic agents for the management of severe community-acquired pneumonia. They are characterized by advantageous pharmacokinetic properties; higher concentrations in the lungs; and an excellent safety profile comparable to other antibiotics used to treat respiratory infections, such as macrolides and b-lactams. Based on their potential antiviral activity and immunomodulatory properties, the favorable pharmacokinetics and safety profile, we propose the use of respiratory fluoroquinolones as adjuncts in the treatment of SARS-CoV-2 associated pneumonia.


Subject(s)
Antiviral Agents/therapeutic use , COVID-19/drug therapy , Levofloxacin/therapeutic use , Moxifloxacin/therapeutic use , Humans , SARS-CoV-2
9.
J Affect Disord ; 277: 337-340, 2020 12 01.
Article in English | MEDLINE | ID: covidwho-722855

ABSTRACT

BACKGROUND: In December 2019, the novel coronavirus (SARS-CoV-2) infection was first reported in Wuhan city, central China, which has spread rapidly. The common clinical features of patients with SARS-CoV-2 infection included fever, fatigue, and damage to the respiratory or digestive system. However, it is still unclear whether SARS-CoV-2 infection could cause damage to the central nervous system (CNS) inducing psychiatric symptoms. CASE REPORT: Herein, we present the first case of SARS-CoV-2 infection with manic-like symptoms and describe the diagnosis, clinical course, and treatment of the case, focusing on the identifications of SARS-CoV-2 in the specimen of cerebrospinal fluid (CSF). The patient developed manic-like symptoms when his vital signs recovered on illness day 17. After manic-like attack, the detection of SARS-CoV-2 specific IgG antibody in CSF was positive, while the reverse transcriptase-polymerase chain reaction (RT-PCR) on CSF for the SARS-CoV-2 was negative. The patient received Olanzapine for treatment and his mood problems concurrently improved as indicated by scores of Young Manic Rating Scale (YMRS). LIMITATION: This is a single case report only, and the RT-PCR test for SARS-CoV-2 in CSF was not performed simultaneously when SARS-CoV-2 was positive in samples of sputum and stool. CONCLUSION: This first case of COVID-19 patient with manic-like symptoms highlights the importance of evaluation of mental health status and may contribute to our understanding of potential risk of CNS impairments by SARS-CoV-2 infection.


Subject(s)
Bipolar Disorder/etiology , Coronavirus Infections/complications , Pneumonia, Viral/complications , Antibodies, Viral/cerebrospinal fluid , Antipsychotic Agents/therapeutic use , Antiviral Agents/therapeutic use , Betacoronavirus , Bipolar Disorder/cerebrospinal fluid , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Brain/diagnostic imaging , COVID-19 , COVID-19 Testing , Chest Pain , China , Clinical Laboratory Techniques , Cobicistat/therapeutic use , Coronavirus Infections/cerebrospinal fluid , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Darunavir/therapeutic use , Dyspnea , Fever , Glucocorticoids/therapeutic use , Humans , Indoles/therapeutic use , Magnetic Resonance Imaging , Male , Methylprednisolone/therapeutic use , Middle Aged , Moxifloxacin/therapeutic use , Olanzapine/therapeutic use , Pandemics , Pharyngitis , Pneumonia, Viral/cerebrospinal fluid , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2
10.
Clin Rheumatol ; 39(9): 2803-2810, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-679748

ABSTRACT

COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old woman, diagnosed with SLE 15 years ago, whose overall clinical characteristics (symptoms, laboratory tests, and chest CTs) were similar to those of the general COVID-19 patients. She continued to take the previous SLE drugs (doses of glucocorticoids, hydroxychloroquine, and immunosuppressive agents were not reduced) and was treated with strict antiviral and infection prevention treatment. After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy. Finally, this long-term immune suppressive patient's COVID-19 was successfully cured. The successful recovery of this case has significant reference value for the future treatment of COVID-19 patients with SLE. Key Points • COVID-19 patients with SLE is advocated to continue the medical treatment for SLE. • Hydroxychloroquine may have potential benefits for COVID-19 patients with SLE. • COVID-19 patients with SLE is prone to relapse, and multiple follow-ups are necessary.


Subject(s)
Antirheumatic Agents/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/drug therapy , Glucocorticoids/therapeutic use , Hydroxychloroquine/therapeutic use , Immunosuppressive Agents/therapeutic use , Lopinavir/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Pneumonia, Viral/drug therapy , RNA, Viral , Ritonavir/therapeutic use , Adult , Anti-Bacterial Agents/therapeutic use , Betacoronavirus , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Drug Combinations , Female , Humans , Lung/diagnostic imaging , Lupus Erythematosus, Systemic/complications , Moxifloxacin/therapeutic use , Mycophenolic Acid/therapeutic use , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Prednisone/therapeutic use , Recurrence , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Tomography, X-Ray Computed
11.
Indian J Ophthalmol ; 68(8): 1675-1677, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-679354

ABSTRACT

A 65-year-old known diabetic, hypertensive, and asthmatic patient was admitted for suspected coronavirus disease 19 (COVID-19) infection following complaints of breathlessness. He tested positive for COVID-19 and was put on ventilation. He developed severe follicular conjunctivitis of the right eye while on a ventilator, which was treated conservatively. The resolution of ocular signs was noted over 2 weeks without any complications. This case highlights the timeline of events and discusses the late ophthalmic manifestations in patients with COVID-19 infection.


Subject(s)
Betacoronavirus , Conjunctivitis, Viral/diagnosis , Coronavirus Infections/diagnosis , Eye Infections, Viral/diagnosis , Pneumonia, Viral/diagnosis , Respiration, Artificial , Aged , Anti-Bacterial Agents/therapeutic use , COVID-19 , Conjunctivitis, Viral/drug therapy , Conjunctivitis, Viral/physiopathology , Coronavirus Infections/drug therapy , Coronavirus Infections/physiopathology , Eye Infections, Viral/drug therapy , Eye Infections, Viral/physiopathology , Follow-Up Studies , Humans , Lubricants/administration & dosage , Male , Moxifloxacin/therapeutic use , Ophthalmic Solutions , Pandemics , Pneumonia, Viral/drug therapy , Pneumonia, Viral/physiopathology , SARS-CoV-2
12.
Am J Trop Med Hyg ; 102(6): 1210-1213, 2020 06.
Article in English | MEDLINE | ID: covidwho-596941

ABSTRACT

Novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has become a public health emergency of international concern. This was first noted in Wuhan, Hubei Province, China, and since then has become widespread globally. We report a 71-year-old woman with documented viral shedding (based on reverse transcription-polymerase chain reaction (RT-PCR) testing) of SARS-CoV-2 for 60 days from the onset of symptoms (55 days from her first positive test and 36 days after complete resolution of symptoms). This is to our knowledge the longest duration of viral shedding reported to date. This case demonstrates that viral shedding after COVID-19 diagnosis can be prolonged.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/diagnostic imaging , Lung/diagnostic imaging , Pneumonia, Viral/diagnostic imaging , Virus Shedding , Acids, Carbocyclic , Aged , Betacoronavirus/drug effects , Betacoronavirus/isolation & purification , COVID-19 , China , Coronavirus Infections/immunology , Coronavirus Infections/pathology , Coronavirus Infections/therapy , Cyclopentanes/therapeutic use , Extracorporeal Membrane Oxygenation , Female , Guanidines/therapeutic use , Humans , Indoles/therapeutic use , Lung/drug effects , Lung/pathology , Lung/virology , Moxifloxacin/therapeutic use , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/pathology , Pneumonia, Viral/therapy , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
13.
Complement Ther Med ; 52: 102473, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-591555

ABSTRACT

OBJECTIVE: Presentation of a case illustrating the benefits of traditional Chinese medicine (TCM) for treatment of Coronavirus disease 2019 (COVID-19) in critically ill patients. CLINICAL FEATURES AND OUTCOME: A 58-year-old woman presented with cough, fever, dizziness, chest tightness, polypnea and poor appetite. She was admitted to Guizhou Provincial People's hospital, and diagnosed with critically ill type of COVID-19 in February 2020. According to the patient's symptoms and signs, the TCM syndrome differentiation was qi deficiency, dampness-stasis and toxin accumulation. Then she received the combined therapy of a modified Chinese herbal formula and Western medicine. During a twelve-day period of treatment, her respiratory distress and appetite quickly improved. Abnormal laboratory indicators were resumed in time and lung lesions in CT scan largely absorbed. No side effects associated with this Chinese herbal formula were found. Before discharge, two consecutive nasopharyngeal swabs were shown to be negative for severe acute respiratory coronavirus 2 (SARS-CoV-2). CONCLUSIONS: Our case report suggests that collaborative treatments with traditional Chinese medicine prove beneficial in the management of COVID-19 in critically ill patients. In order to give optimal care for this COVID-19 crisis for the whole world, Chinese medicine practitioners and Western medical doctors should work together in frontline.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Antiviral Agents/therapeutic use , Coronavirus Infections/drug therapy , Drugs, Chinese Herbal/therapeutic use , Medicine, Chinese Traditional , Pneumonia, Viral/drug therapy , Betacoronavirus , COVID-19 , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Critical Illness , Drug Combinations , Female , Humans , Indoles/therapeutic use , Lopinavir/therapeutic use , Methylprednisolone/therapeutic use , Middle Aged , Moxifloxacin/therapeutic use , Noninvasive Ventilation , Oxygen Inhalation Therapy , Pandemics , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Qi , Ritonavir/therapeutic use , SARS-CoV-2
14.
Acta Ophthalmol ; 98(8): 859-863, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-260153

ABSTRACT

BACKGROUND: The current outbreak of COVID-19 has spread rapidly all over the world. Respiratory droplets and contaction with infected patients are the two major transmission routes. However, the value of tear virus nucleic acid is still not clear. We dynamic detected the SARS-CoV-2 in eye sample of one COVID-19 patient with obstruction of common lacrimal ducts. METHODS: Besides the routine examination, nasopharyngeal and eye swab were continuously measured by polymerase chain reaction assay and next-generation sequencing (NGS). Gene detection was performed for drug use guidance, and flow cytometry was performed to analyse the lymphocyte subsets. RESULTS: Nasopharyngeal swabs were positive for 22 days, but eye swabs were still continuously positive for 2 weeks after nasopharyngeal swabs turned negative. The low level of lymphocyte and the high level IL-6 lasted for almost 4 weeks, then became near normal. Next-generation sequencing (NGS) confirmed the existing of SARS-CoV-2, HSV1 and HHV6B virus nucleic acid. The gene detection for drug use guidance showed the genetic locus ABCB1 (3435T>C) rs1045642 belonged to type CC and it mean the efficiency of lopinavir-ritonavir would be significantly decreased. The flow cytometry of lymphocyte subsets showed PD-1+  CD95+ cells was accounting for 94.8% in CD3+  CD8+ T subset and for 94.8% in CD3+  TCRγδ+ T subset. CONCLUSIONS: As obstruction of common lacrimal duct, positively detection in one eye for 2 weeks more after nasopharyngeal swab became negative. More eye swabs should be collected from COVID-19 patients, especially from those immunocompromised, those with eye symptoms and those had a history of ocular diseases.


Subject(s)
COVID-19/diagnosis , Conjunctiva/virology , Eye Infections, Viral/diagnosis , Herpesvirus 1, Human/isolation & purification , Herpesvirus 6, Human/isolation & purification , Lacrimal Duct Obstruction/diagnosis , SARS-CoV-2/isolation & purification , Tears/virology , Aged , Anti-Bacterial Agents/therapeutic use , COVID-19/drug therapy , COVID-19/virology , Conjunctivitis, Viral/diagnosis , Drug Therapy, Combination , Eye Infections, Viral/drug therapy , Eye Infections, Viral/virology , Flow Cytometry , HIV Protease Inhibitors/therapeutic use , Herpes Simplex/diagnosis , Herpes Simplex/drug therapy , Herpes Simplex/virology , Herpesvirus 1, Human/genetics , Herpesvirus 6, Human/genetics , High-Throughput Nucleotide Sequencing , Humans , Lacrimal Duct Obstruction/drug therapy , Lacrimal Duct Obstruction/virology , Lopinavir/therapeutic use , Male , Medicine, Chinese Traditional , Moxifloxacin/therapeutic use , Nasopharynx/virology , Nucleic Acids/genetics , Polymerase Chain Reaction , RNA, Viral/genetics , Ritonavir/therapeutic use , Roseolovirus Infections/diagnosis , Roseolovirus Infections/drug therapy , Roseolovirus Infections/virology , SARS-CoV-2/genetics
16.
J Med Virol ; 92(6): 683-687, 2020 06.
Article in English | MEDLINE | ID: covidwho-10401

ABSTRACT

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 has become an important public health issue in the world. More than 118 000 cases were confirmed around the world. The main clinical manifestations were respiratory symptoms and occasional gastrointestinal symptoms. However, there is no unified standard for the diagnosis and treatment of COVID-19. In the retrospective analysis, we report nine cases of COVID-19, describe the history of contact, clinical manifestations, the course of diagnosis and clinical treatment before, during and after treatment.


Subject(s)
Betacoronavirus/genetics , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Interferon alpha-2/therapeutic use , Pneumonia, Viral/diagnosis , Pneumonia, Viral/drug therapy , RNA, Viral/genetics , Adolescent , Adult , Betacoronavirus/drug effects , Betacoronavirus/isolation & purification , Betacoronavirus/pathogenicity , COVID-19 , COVID-19 Testing , China , Clinical Laboratory Techniques/methods , Contact Tracing , Coronavirus Infections/immunology , Coronavirus Infections/pathology , Female , Humans , Lopinavir/therapeutic use , Male , Methylprednisolone/therapeutic use , Middle Aged , Moxifloxacin/therapeutic use , Oropharynx/virology , Oxygen/therapeutic use , Pandemics , Pneumonia, Viral/immunology , Pneumonia, Viral/pathology , RNA, Viral/isolation & purification , Retrospective Studies , Ritonavir/therapeutic use , SARS-CoV-2 , Severity of Illness Index , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/virology , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL